

# Anders Mellemsgaard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7043302/publications.pdf>

Version: 2024-02-01

28  
papers

1,291  
citations

687363

13  
h-index

580821

25  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. <i>Lancet Oncology</i> , 2014, 15, 143-155.	10.7	823
2	Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2015, 51, 317-326.	2.8	58
3	The prevalence of <sc>EGFR</sc> mutations in non-small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , 2015, 123, 108-115.	2.0	55
4	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35.	2.0	42
5	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230.	2.0	41
6	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study”A Brief Research Report. <i>Frontiers in Immunology</i> , 2018, 9, 2145.	4.8	37
7	Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. <i>Thorax</i> , 2018, 73, 530-537.	5.6	35
8	The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2017, 69, 444-453.	2.0	31
9	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	3.6	30
10	Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. <i>Lung Cancer</i> , 2015, 90, 267-273.	2.0	26
11	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8011-LBA8011.	1.6	19
12	High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. <i>Modern Pathology</i> , 2014, 27, 1590-1598.	5.5	18
13	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. <i>Future Oncology</i> , 2017, 13, 1159-1171.	2.4	17
14	Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold intensity-modulated radiotherapy for locally advanced lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 55-63.	0.6	10
15	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000102.	4.5	9
16	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. <i>Biologics: Targets and Therapy</i> , 2015, 9, 47.	3.2	7
17	Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study. <i>Acta Oncologica</i> , 2017, 56, 335-341.	1.8	7
18	Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8103-8103.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.. Journal of Clinical Oncology, 2017, 35, TPS2610-TPS2610.	1.6	6
20	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study. Scientific Reports, 2021, 11, 16892.	3.3	4
21	The prevalence of <scp>ALK</scp> rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. Histopathology, 2017, 70, 889-895.	2.9	3
22	Intracranial effect of osimertinib in relapsed <i>EGFR</i>-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta OncolÅ³gica, 2021, 60, 1565-1571.	1.8	2
23	Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D).. Journal of Clinical Oncology, 2014, 32, 8100-8100.	1.6	2
24	Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study.. Journal of Clinical Oncology, 2015, 33, e19021-e19021.	1.6	2
25	Retrospective analysis to compare the efficacy of oral (O) vs. intravenous (IV) etoposide given in combination with carboplatin for small cell lung cancer (SCLC), extensive disease (ED).. Journal of Clinical Oncology, 2017, 35, e20020-e20020.	1.6	1
26	Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.. Journal of Clinical Oncology, 2013, 31, LBA8011-LBA8011.	1.6	0
27	Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.. Journal of Clinical Oncology, 2013, 31, 8084-8084.	1.6	0
28	Programmed cell death receptor ligand 1 (PD-L1) expression: Epidermal growth factor receptor (<i>EGFR</i>) and <i>Kirsten RAS</i> (KRAS) mutations in second-line therapy (2L) non-small cell lung cancer (NSCLC) patientsâ€™A Danish cohort study.. Journal of Clinical Oncology, 2017, 35, e20523-e20523.	1.6	0